



SUCCESS OF THE LISA-TRACKER SYMPOSIUM DURING VIDEO DIGEST 2013

Key Opinion Leaders highlight the importance of anti-TNF dosage and monitoring as part of the management of patients treated with biotherapies

Croissy-Beaubourg and Montpellier, November 20, 2013 – THERADIAG (ISIN : FR0004197747, Ticker: ALTER), a company specializing in theranostics and *in vitro* diagnostics (IVD), announced today that the symposium dedicated to the dosage of anti-TNF α , made available by the Lisa Tracker theranostics range, was very well received by gastroenterologists. The symposium was organized by Theradiag as part of Video Digest 2013 - the French annual meeting dedicated to digestive endoscopy.

Invited to speak on the treatment and monitoring of patients treated with biotherapies, Xavier Robin, M.D., Ph.D., and Stéphane Paul, M.D., based in Saint-Etienne University Hospital, and Jérôme Filippi, M.D. working at Nice University Hospital, discussed the loss of efficacy of anti-TNF α therapies over time. They highlighted the need to measure and monitor trough levels of anti-TNF α (drug) and anti-drug antibodies (ADAb) in order to adapt treatments to the specific needs of patients – the main purpose of theranostics.

“The immunogenicity of biotherapies has been established, no matter the type of antibody used. They must be monitored to identify the appropriate treatment” comments Dr. Paul.

The 3 experts attested to the benefits of dosage in addition to a clinical approach in order to obtain long-lasting clinical remission. They illustrated with numerous works the value of dosage as reliable tools in the assessment, for example, of mucosal healing in inflammatory bowel diseases (IBD), for which drug serum levels are correlated with patient outcomes.

“The dosage of anti-TNF α is critical given the limited therapeutic options that are available in gastroenterology. They allow us to have patient-tailored treatment options” said Pr. Roblin.

Dr. Filippi adds: *“We must keep the risk/benefit ratio in mind in the long run, especially for patients in long-term remission taking immunosuppressant biotherapies. For these patients, as shown by recent studies, anti-TNF α dosage could help determine who will remain in remission while maintaining satisfactory trough levels”*.

The experts agreed that the monitoring of anti-TNFs and ADAb levels contribute to improved patient care, not only in the case of therapeutic failure but also as part of therapeutic de-escalation strategies. They could notably help predict the risk of relapse when treatments are discontinued.



New validation of Lisa-Tracker, the theranostic tool for anti-TNF α monitoring

Revenues of Lisa-Tracker, one of Theradiag's proprietary theranostics portfolio, have increased strongly since market approval in 2011 (+56% in 2012 and +142% in H1 2013). Lisa-Tracker is now used by laboratories and physicians in 15 countries worldwide.

"The growing interest of experts and clinicians for our Lisa-Tracker portfolio is a great reward. It speaks to the therapeutic and economic interest of our theranostics assays which address patient needs and concerns of all actors of the healthcare systems. Our theranostics range is becoming a reference in the treatment of auto-immune diseases" concludes Michel Finance, CEO of Theradiag.

About Lisa Tracker

The LISA TRACKER kits are the first CE marked kits allowing simultaneous or single dosage of those parameters within three hours of reaction from a serum sample:

- Prescribed anti-TNF- α (Infliximab, Adalimumab, Etanercept, Certolizumab-pegol, golimumab) to optimize dosage consistent with the presence or absence of ADAb.
- The presence of antibodies directed against the drug (ADAb), a strong marker of loss of drug efficacy.
- Circulating TNF α , one of the main markers involved in the inflammatory process.

The combination of these parameters allows clinicians to anticipate, optimize, and better manage the patient's treatment.

About Theradiag

Leveraging its expertise in the distribution, development and manufacturing of *in vitro* diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag is thus participating in the development of "personalized treatment", which favors the individualization of treatments, the evaluation of their efficiency and the prevention of drug resistance. Theradiag markets the Lisa-Tracker range (CE marked), which is a comprehensive multiparameter diagnosis solution for patients with autoimmune diseases treated with biotherapies. Theradiag is also developing new diagnostic markers thanks to its microRNA platform, which will allow specific biomarkers to be identified in order to guide therapy and will be first and foremost applied to the treatment of AIDS. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 50 employees.

For more information about Theradiag, please visit our website: www.theradiag.com



Theradiag

Relations investisseurs

Nathalie Trepo

Tél: 01 64 62 10 12

ntrepo@theradiag.com

NewCap.

Communication financière
et Relations Investisseurs

Valentine Brouchet /

Pierre Laurent

Tél. : 01 44 71 98 52

theradiag@newcap.fr

Alize RP

Relations Presse

Caroline Carmagnol

caroline@alizerp.com

Tél. : 06 64 18 99 59

Christian Berg

christian@alizerp.com

Tél. : 01 70 22 53 86